BioXcell：InVivoMAb anti-mouse CD172a (SIRPα)單克隆抗體

P84單克隆抗體，也被稱為CD172a抗體，可與信號(hào)調(diào)節(jié)蛋白α(SIRPα)反應(yīng)。SIRPα蛋白是I型跨膜糖蛋白，在單核細(xì)胞、巨噬細(xì)胞和樹突狀細(xì)胞均有表達(dá)。此外，在神經(jīng)元和中樞神經(jīng)系統(tǒng)的一些其他組織也發(fā)現(xiàn)有SIRPα蛋白的表達(dá)。其配體CD47在多種細(xì)胞均有表達(dá)。

SIRPα和CD47參與調(diào)節(jié)由樹突狀細(xì)胞介導(dǎo)的T細(xì)胞的活化、中性粒細(xì)胞遷移和吞噬等過程。SIRPα蛋白可在巨噬細(xì)胞的細(xì)胞膜上進(jìn)行橫向擴(kuò)散并在吞噬性突觸中積累，與CD47結(jié)合后，抑制巨噬細(xì)胞的吞噬作用。

研究結(jié)果表明，使用anti-SIRPα抗體阻斷SIRPα與CD47相互作用，可抑制小鼠體內(nèi)腫瘤的形成。此外，P84（CD172a）單克隆抗體在體內(nèi)和體外均具有中和活性。

BioXcell最新推出InVivoMAb anti-mouse CD172a (SIRPα)單克隆抗體，助力腫瘤免疫檢查點(diǎn)研究。如需購(gòu)買BioXcell公司產(chǎn)品，請(qǐng)聯(lián)系代理商欣博盛生物。

產(chǎn)品信息：

Application References:

Yanagita, T., et al. (2017). 'Anti-SIRPalpha antibodies as a potential new tool for cancer immunotherapy.' JCI Insight 2(1): e89140. 

Koskinen, C., et al. (2013). 'Lack of CD47 impairs bone cell differentiation and results in an osteopenic phenotype in vivo due to impaired signal regulatory protein alpha (SIRPalpha) signaling.' J Biol Chem 288(41): 29333-29344. 

Teraoka, Y., et al. (2013). 'Expression of recipient CD47 on rat insulinoma cell xenografts prevents macrophage-mediated rejection through SIRPalpha inhibitory signaling in mice.' PLoS One 8(3): e58359. 

Zen, K., et al. (2013). 'Inflammation-induced proteolytic processing of the SIRPalpha cytoplasmic ITIM in neutrophils propagates a proinflammatory state.' Nat Commun 4: 2436.

Lundberg, P., et al. (2007). 'Osteoclast formation is strongly reduced both in vivo and in vitro in the absence of CD47/SIRPalpha-interaction.' Biochem Biophys Res Commun 352(2): 444-448. 

Oldenborg, P. A., et al. (2001). 'CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis.' J Exp Med 193(7): 855-862.